News | May 21, 2010

Biodegradable Stent Preserves Mechanical Strength


May 21, 2010 – Results of an in vivo study of 48 porcine arteries implanted with a biodegradable stent showed biodegradation is measurable and begins at the first day of implant. However, high radial strength is maintained during biodegradation.

These results were released this week by Arterial Remodeling Technologies (ART), which is developing bioresorbable coronary polylactic acid polymer stents that promote the natural remodeling of an injured artery after angioplasty.

Previous validating data regarding ART’s next-generation bioresorbable stent approach has been published in the January 2010 special supplement of EuroIntervention. The paper was authored by Antoine Lafont, M.D., Ph.D., Head, Interventional Cardiology Department, Georges Pompidou Hospital, Paris.

The stent is designed to provide an impermanent scaffold that will dismantle and loose its primary mechanical function after three months. This is the period when most experts say is it is necessary to permit the healing process to stabilize the artery following the trauma caused by an angioplasty. The complete resorption of all the polymer is estimated to occur within 18 months.

ART said its stent is designed to have several competitive benefits over existing bioresorbable stents in development. These include faster and smoother resorption, use of a non-crystalline polymer, better stress diffusion, and crack-free expansion. The ART device is designed for conventional balloon stent delivery and meets the market standard of 6 French compatibility.

For more information: www.art-stent.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now